These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Reduction in cardiovascular and all-cause mortality in the EMPA-REG OUTCOME trial: A critical analysis. Scheen AJ Diabetes Metab; 2016 Apr; 42(2):71-6. PubMed ID: 26856453 [No Abstract] [Full Text] [Related]
5. Asian Perspective of the EMPA-REG OUTCOME Study. Bando YK; Murohara T Circ J; 2017 Jan; 81(2):155-157. PubMed ID: 28111376 [No Abstract] [Full Text] [Related]
6. The EMPA-REG study: What has it told us? A diabetologist's perspective. DeFronzo RA J Diabetes Complications; 2016; 30(1):1-2. PubMed ID: 26541076 [No Abstract] [Full Text] [Related]
7. EMPA-REG OUTCOME: The Endocrinologist's Point of View. Perreault L Am J Med; 2017 Jun; 130(6S):S51-S56. PubMed ID: 28526185 [TBL] [Abstract][Full Text] [Related]
8. EMPA-REG OUTCOME: The Endocrinologist's Point of View. Perreault L Am J Cardiol; 2017 Jul; 120(1S):S48-S52. PubMed ID: 28606344 [TBL] [Abstract][Full Text] [Related]
10. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. Edwards JL N Engl J Med; 2016 Mar; 374(11):1093. PubMed ID: 26981943 [No Abstract] [Full Text] [Related]
11. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. Zinman B; Lachin JM; Inzucchi SE N Engl J Med; 2016 Mar; 374(11):1094. PubMed ID: 26981940 [No Abstract] [Full Text] [Related]
12. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. Sarafidis PA; Tsapas A N Engl J Med; 2016 Mar; 374(11):1092. PubMed ID: 26981941 [No Abstract] [Full Text] [Related]
13. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. Fischereder M; Schönermarck U N Engl J Med; 2016 Mar; 374(11):1092-3. PubMed ID: 26981942 [No Abstract] [Full Text] [Related]
14. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. Rosenstein R; Hough A N Engl J Med; 2016 Mar; 374(11):1093-4. PubMed ID: 26981944 [No Abstract] [Full Text] [Related]
15. EMPA-REG OUTCOME: The Cardiologist's Point of View. Pham SV; Chilton RJ Am J Cardiol; 2017 Jul; 120(1S):S53-S58. PubMed ID: 28606345 [TBL] [Abstract][Full Text] [Related]
16. Preventing cardiovascular events with empagliflozin: at what cost? Naci H; Basu S; Yudkin JS Lancet Diabetes Endocrinol; 2015 Dec; 3(12):931. PubMed ID: 26590682 [No Abstract] [Full Text] [Related]
17. Cardiovascular Risk and Sodium-Glucose Cotransporter 2 Inhibition in Type 2 Diabetes. Ingelfinger JR; Rosen CJ N Engl J Med; 2015 Nov; 373(22):2178-9. PubMed ID: 26605932 [No Abstract] [Full Text] [Related]
19. Absolute benefits of empagliflozin in type 2 diabetes: a game changer? Kumana CR; Tan KCB; Cheung BMY Postgrad Med J; 2017 Jul; 93(1101):373-375. PubMed ID: 28433975 [No Abstract] [Full Text] [Related]